(Ray) Yu Chen Su
About (Ray) Yu Chen Su
Ray Yu Chen Su serves as the Director and Head of Biostatistics and Programming at Inari Medical, where he has worked since 2020. He has extensive experience in biostatistics, having held various roles in notable organizations and contributed significantly to clinical study design and real-world evidence generation.
Work at Inari Medical
Currently, Yu Chen Su serves as the Director and Head of Biostatistics and Programming at Inari Medical, a position held since 2020. In this role, he leads the biostatistics and programming team, fostering a player-coach mentality that emphasizes both hands-on involvement and management guidance. His leadership focuses on the design and implementation of clinical studies, ensuring adherence to regulatory standards and best practices in biostatistics.
Education and Expertise
Yu Chen Su holds a Doctor of Philosophy (PhD) in Biostatistics/Statistical Genetics from the University of Southern California and a Master of Science (M.S.) in Biostatistics/Genetic Epidemiology from Washington University School of Medicine in St. Louis. He also earned a Bachelor of Science (B.S.) in Biomedical Engineering from Washington University in St. Louis. His educational background provides a strong foundation in statistical methodologies and their applications in clinical research.
Professional Background
Yu Chen Su has a diverse professional background in biostatistics and programming, having worked in various capacities across multiple organizations. His career includes roles as Principal Biostatistician at Biogen, where he focused on Real World Evidence, and as a Lead Biostatistician/Data Scientist at Neural Analytics. He has also held positions at Edwards Lifesciences, Takeda Pharmaceuticals, and several roles at the University of Southern California, contributing to both academic and industry research.
Achievements in Clinical Research
Throughout his career, Yu Chen Su has made significant contributions to clinical research, particularly in the field of venous thromboembolism. He has been involved in the design of clinical studies utilizing adaptive designs and win ratio outcomes. His work includes the implementation of the CDISC process for various clinical studies and real-world registries, such as PEERLESS, DEFIANCE, FLASH, CLOUT, FLAME, and FLARE-FT2. He has also applied advanced causal inference methodologies to generate real-world evidence for conferences and publications.